Free tool
FAERS Monitor: Tolak
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022259 or its brand name (Tolak, Fluorouracil). Reports on generic versions are filed under their own applications.
Reports
77,744
Serious
73,787
95% of reports
Hospitalization
31,318
Death reported
10,973
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea7,085
- neutropenia5,296
- nausea5,071
- vomiting4,044
- off label use3,630
- neuropathy peripheral3,541
- fatigue3,324
- disease progression3,293
- pyrexia3,093
- thrombocytopenia3,036
- febrile neutropenia2,916
- anaemia2,612
- asthenia2,592
- drug ineffective2,242
- malignant neoplasm progression2,217
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,695 |
| 2005 | 1,687 |
| 2006 | 1,392 |
| 2007 | 1,586 |
| 2008 | 1,848 |
| 2009 | 1,815 |
| 2010 | 1,692 |
| 2011 | 2,338 |
| 2012 | 2,862 |
| 2013 | 2,240 |
| 2014 | 1,876 |
| 2015 | 2,381 |
| 2016 | 2,755 |
| 2017 | 3,206 |
| 2018 | 4,849 |
| 2019 | 5,101 |
| 2020 | 4,268 |
| 2021 | 4,269 |
| 2022 | 5,740 |
| 2023 | 6,336 |
| 2024 | 6,005 |
| 2025 | 6,709 |
| 2026 | 5,094 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,976,415 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 2,916 | 12.4 | 11.9 | 29,282 |
| neutropeniaSignal | 5,296 | 10.9 | 10.6 | 46,176 |
| neuropathy peripheralSignal | 3,541 | 10.4 | 10.1 | 29,160 |
| disease progressionSignal | 3,293 | 7.7 | 7.5 | 18,813 |
| thrombocytopeniaSignal | 3,036 | 7.5 | 7.3 | 16,785 |
| malignant neoplasm progressionSignal | 2,217 | 6.0 | 5.7 | 9,001 |
| anaemiaSignal | 2,612 | 3.7 | 3.6 | 5,222 |
| diarrhoeaSignal | 7,085 | 3.0 | 2.9 | 9,581 |
| pyrexiaSignal | 3,093 | 2.4 | 2.3 | 2,624 |
| vomitingSignal | 4,044 | 2.3 | 2.3 | 3,140 |
| asthenia | 2,592 | 1.9 | 1.8 | 1,062 |
| nausea | 5,071 | 1.7 | 1.7 | 1,640 |
| fatigue | 3,324 | 1.2 | 1.1 | 72 |
| off label use | 3,630 | 1.1 | 1.1 | 50 |
| drug ineffective | 2,242 | 0.5 | 0.4 | 1,519 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.